



Day 1			
Monday, 17 th February 2025			
AKU Auditorium			
08:00 AM – 09:00 AM	00 AM – 09:00 AM Summit Check-In		
	Opening Ceremony		
Time	Title	Speaker	
09:00 AM – 09:05 AM	Recitation of the Holy Quran		
09:05 AM – 09:10 AM	National Anthem		
09:10 AM – 09:20 AM	Welcome Address & Overview of	Dr. Saeed Hamid,	
	Summit	Director, Clinical Trials Unit, AKU	
09:20 AM – 09:45 AM	High level messages:	Dr. Farhat Abbas,	
	Shaping the Future of Clinical	CEO, Aga Khan University Hospital	
	Trials in Pakistan	Dr. Wasim Alamgir,	
		V.C, National University of Medical Sciences	
		Mr. Asim Rauf,	
		CEO, Drug Regulatory Authority of	
		Pakistan	
		Dr. Arash Rashidian,	
		Director of Science Information and	
		Dissemination, WHO EMRO	
		Dr. Salim Virani,	
		Vice Provost Research, The Aga Khan	
	enter 4. Delictor Olivie el Triole	University	
	Session 1- Pakistan Clinical Trials Landscape		
	Dr. Saleem Ahmed Khan (Retd.), Executi Khan, Chair Family Medicine, AKU	IVE DIRECTOR R&C NUMS	
Time	Title	Speaker	
09:45 AM – 10:00 AM	Pakistan Clinical Trials Landscape	Dr. Baber Saeed Khan	
00.107.11 10.007.11	report	Director, CTU NUMS	
10:00 AM – 10:15 AM	Disease Patterns in Pakistan and	Dr. Zainab Samad	
	their impact on clinical trials	Chair, Department of Medicine, AKU	
10:15 AM – 10:55 AM	Data on Focus Therapeutic Areas		
	Pak Sehat: Mini Framingham of	Dr. Bashir Hanif	
	Pakistan, a longitudinal cohort for	Consultant Cardiologist, Principal	
	cardiovascular disease	Investigator PAK-SEHAT, Executive	
	First Landing Co. 1. C	Director, Tabba Heart Institute	
	First Longitudinal Study of	Dr. Adeel Khoja	
	Cardiovascular Risk Assessment	Assistant Professor, Department of Medicine, AKU	
	Among Adolescents and Young	Medicille, AND	
	Adults in Pakistan (LIFE CARD)		





	I	
	Lessons learnt from the Diabetes	Dr. Abdul Basit
	Registry of Pakistan	Professor and Head, Diabetes and
		Endocrine Centre, Indus Hospital and
		Health Network. Principal
		Investigator, Diabetes Registry of
		Pakistan (DROP), Vice Chairman,
		Health Research Advisory
		Board (HealthRAB)
	Cancer Registration in Pakistan:	Dr. Shahid Pervez
	Current Status	Professor & Consultant
		Histopathologist,
		Department of Pathology &
		Laboratory Medicine, AKU
10:55 AM - 11:10 AM	Q/A session	
11:10 AM - 11:35 AM	Coffee & Tea	
Session 2: Wh	HO Session- Best Practices to St	rengthen Clinical Trials
Session Chair 1: Dr. S. M.	Wasim Jafri, Founding President Pakistan	Society for Study of Liver Diseases
Session Chair 2: Dr. Asad	Ali, Chair Community Health Sciences, A	KU
Time	Title	Speaker
11:35 AM – 11:55 AM	Plenary Talk	Dr. Arash Rashidian
	WHO strategies for enhancing the	Director of Science Information and
	conduct and use of research for	Dissemination, WHO EMRO
	health in the EMRO region	
11:55 AM – 12:15 PM	Plenary Talk	Dr. Vasee Moorthy
	WHO Normative guidance for best	Senior Advisor, R&D Science
	practices in Clinical Trials	Division, WHO HQ
12:15 PM - 12:30 PM	Preliminary results of EMRO wide	Dr. Arshad Altaf
	landscape analysis of national	Science, Information and
	clinical trials ecosystems	Dissemination (SID)
		WHO EMRO
12:30 PM - 12:45 PM	Iran's experience of RCT conduct	WHO EMRO Dr. Akbar Fotouhi
12:30 PM - 12:45 PM	Iran's experience of RCT conduct and governance	Dr. Akbar Fotouhi Professor of Epidemiology,
12:30 PM - 12:45 PM	' '	Dr. Akbar Fotouhi
12:30 PM - 12:45 PM	' '	Dr. Akbar Fotouhi Professor of Epidemiology,
12:30 PM - 12:45 PM	' '	Dr. Akbar Fotouhi Professor of Epidemiology, Department of Epidemiology and
12:30 PM - 12:45 PM	' '	Dr. Akbar Fotouhi Professor of Epidemiology, Department of Epidemiology and Biostatistics, School of Public
12:30 PM - 12:45 PM 12:45 PM- 01:00 PM	' '	Dr. Akbar Fotouhi Professor of Epidemiology, Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical





Session 3- Regulatory Framework Analysis- Global Best Practices Session Chair 1: Dr. Obaidullah, Director Drug Regulatory Authority of Pakistan (DRAP) Session Chair 2: Mr. Abdullah Abro, Chair Clinical Studies Committee, DRAP

Session Chair 2: Mr. Ab	ion Chair 2: Mr. Abdullan Abro, Chair Clinical Studies Committee, DRAP			
Time	Title	Speaker		
02:00 PM – 03:35 PM	DRAP's Role in Advancing Clinical	Dr. Obaidullah		
	Trials in Pakistan	Director Drug Regulatory Authority of		
		Pakistan		
	From Bench to Bedside to	Prof. Dr. Shahrukh Hashmi		
	Globalization	Professor of Medicine, Mayo Clinic,		
		US, Professor of Computer Vision,		
		MBZ University of AI, Hematology		
		Consultant, Abu Dhabi, UAE		
	MHRA Regulatory Perspective on	Dr. Essam Kerwash		
	First in Human Clinical Trials	Leading Senior Clinical		
		Pharmacology Assessor, MHRA		
	Current issues in Clinical Trials:	Dr. Iftekhar Khan		
	Experiences from the European	Former Expert Statistical Assessor		
	Medicines Agency	EMA and MHRA		
	Transforming Malaysia into a	Ms. Audrey Ooi		
	Preferred Destination for Clinical	Head of Business Development		
	Trials- Insights from Clinical	Clinical Research Malaysia		
	Research Malaysia			
	New Drug Application- Regulatory	Dr. Iftekhar Mahmood		
	and Scientific Aspects	Independent Consultant		
	·	Former US FDA Clinical		
		Pharmacologist		
03:35 PM – 03:45 PM	Q/A session			
03:45 PM – 04:00 PM	Coffee & Tea			

Session Chair 1: Prof. Dr. Saima Pervaiz Iqbal, Chairperson NBC-R, Pakistan Session Chair 2: Dr. Robyna Khan, Chair of Ethics Review Board, AKU				
Time	Title Speaker			
04:00 PM – 04:15 PM	Role of National Bioethics Dr. Faiza Bashir			
	Committee- Advancing ethical	Focal Person National Bioethics		
	efficiency	Committee for Research. Health		
	Research Institute, NIH.			
04:15 PM – 04:30 PM	Introducing Iran's Medical	Dr. Akbar Fotouhi		
	Research Ethics System	Professor of Epidemiology,		
		Department of Epidemiology and		

Session 4- Ethical Considerations in Clinical Trials

Sciences

Biostatistics, School of Public Health, Tehran University of Medical





04:30 PM – 04:45 PM	The work of AKU Ethics Review	Dr. Asad Ali
	Committees in enhancing clinical	Chair Community Health Sciences,
	trials activity	AKU
04:45 PM – 05:00 PM	Balancing Risk and Benefit in Trial	Dr. Aamir Jafarey
	Design	Professor at Centre of Biomedical
		Ethics and Culture, Sindh Institute of
		Urology and Transplantation
05:00 PM – 05:15 PM	Q/A session	

Session 5- Advancing Oncology Clinical Trials in Pakistan-Building Consortia for Better Access

Session Chair 1: Dr. Zehra Fadoo, Chair Oncology, AKU

Session Chair 2: Dr. Adnan Jabbar, Chairman Oncology, Ziauddin University

Session Chair 2: Dr. Adnan .	Jabbar, Chairman Oncology, Ziauddin U	niversity
Time	Title	Speaker
05:15 PM – 05:35 PM	Plenary Talk:	Dr. Khalid Matin
	Improving Inclusion and Access	Professor of Medicine
	for Oncology Clinical Trials:	Division of Hematology, Oncology &
	Lessons Learned in the USA and	Palliative Care, Associate
	Global Implications	Director, Global Oncology
		VCU Massey Comprehensive Cancer
		Center, USA
05:35 PM – 05:55 PM	Plenary Talk:	Dr. Shaalan Beg
	Building a Strong Oncology	Adjunct Associate Professor
	Research Ecosystem: US Insights	University of Texas, Southwestern
	for Pakistan	Medical School, Dallas, USA
05:55 PM – 06:10 PM	Enhancing Clinical Trial	Dr. James Kyle Bryan
	Accessibility in Pakistan:	Chief Medical Officer, IQVIA Biotech
	Collaborative Strategies and	Global Head, IQVIA Hematology-
	Lessons from IQVIA	Oncology Center of Excellence
06:10 PM – 06:25 PM	Navigating the Complexities of	Ms. Mahira El-Kholy
	Oncology Clinical Trials	Global Project Manager, Oncology
		and Rare Disease Clinical Trials, DRK
		Pharma Solutions GmbH
06:25 PM – 06:40 PM	Lessons from the U.S.:	Dr. Mazhar Jaffry
	Successful Models and Case	President/ CEO Revival Research
	Studies in Clinical Trials	Institute, USA
06:40 PM – 06:55 PM	Q & A session	
06:55P M – 07:00 PM	Closing remarks for Day 1	
	Dinner	





Day 2-Tuesday, 18th February 2025 AKU Auditorium

09:00 AM – 09:10 AM Welcome Back: Highlights from Yesterday, Opportunities for Today

Session 6: Collaborative Pathways: Aligning Stakeholders in Clinical Research

Session 6A: Collaboration Among Clinical Trial Units: Strengthening Pakistan's Research Ecosystem

Session Chair 1: Dr. Javed Akram, President Pakistan Society of Internal Medicine Session Chair 2: Dr. Mirza Tasawer, Member Clinical Studies Committee, DRAP

Time	Title	Speaker
09:10 AM – 10:10 AM	 Aga Khan University, Karachi NUMS, Rawalpindi Al-Shifa Trust Eye Hospital, Rawalpindi Shifa International, Islamabad Shaukat Khanum Memorial Cancer Hospital Research Centre (SKMCH&RC), Lahore Dow University & Health Sciences (DUHS), Karachi Ziauddin University, Karachi Rehman Medical Institute (RMI), Peshawar 	Dr. Saeed Hamid Director CTU AKU Dr. Babar Saeed Khan Director, CTU NUMS Dr. Ume Sughra Director Research, Al-Shifa Research Centre Dr. Maimoona Siddiqui Director Shifa Clinical Research Center at Shifa International Hospital. Dr. Farah Asif Director CTU, SKMCH & RC Dr. Izhar M. Hussain Executive Director, DUHS Dr. Zulfiqar Umrani Director CTU, Ziauddin University Dr. Naseer Ahmed Head CTU RMI
10:10 AM – 10:25 AM	Panel Discussion	
10:25 AM – 10:40 AM	Coffee & Tea	

Session 6B: Sponsors' Experience with Clinical Trials in Pakistan

Session Chair 1: Dr. Saeed Hamid, Director CTU, AKU

Session Chair 2: Dr. Malik Muhammad Asad, Deputy Director (Secretary, Clinical Studies Committee) DRAP

10: 40 AM – 11:20 AM	•	Abbott, UK	Dr. Camilla Forssten
	•	Hua Hui Health, China	Principal Clinical Manager, EU
	•	Novo Nordisk, Pakistan	Infectious Disease, Abbott
	•	Getz Pharma	Dr. Bin Chen CEO, Hua Hui Health, China
	•	Pharm Evo	olo, maa mar noattii, olima





	 GSK Hoechst Pakistan Limited Martin Dow	Dr. Atika Shaheer Director Medical, Regulatory and Pharmacovigilance Novo Nordisk Pharma (Pvt.) Ltd
		Dr. Wajiha Javed
		Associate Director Public Health
		& Research, Getz Pharma Pvt. Ltd
		Dr. Masood Jawaid
		Director Medical Affairs
		PharmEvo (Pvt.) Ltd.
		Dr. Yousuf Hasan Khan
		Medical Director, GSK
		Dr. Nadim ur Rehman
		Head of Medical Affairs,
		Hoechst Pakistan Limited
		Dr. Ahmed Nawaz
		Head of Medical Affairs and
		Complaints, Martin Dow
11:20 AM - 11:35 AM	Panel Discussion	

Session 6C: Evolving Roles of CROs and Essential Support Services in Pakistan Clinical Trials Landscape

Session Chair 1: Dr. Rashid Jooma, CEO, Kidney Centre Session Chair 2: Dr. Shafqat Hussain, Deputy Director, DRAP

11:35 AM - 12:15 PM	 Metrics Research IQVIA DRK Pharma Solutions Trials 360 OrciTrials Dimensions Research BNS Logistics 	Dr. Murtaza Hussain CEO, Metrics Research Pvt. Ltd Syed Munawar Ali Head of Clinical Operations, Associate Director, RDS- IQVIA. Syeda Azka Wase Head of Strategy & Corporate Development, DRK Pharma Solutions GmbH Dr. Khushbukhat Khan Oncology Lead, Trials 360 Dr. Ahmad Kamal Clinical Project Manager, OrciTrials
12:15 PM - 12:30 PM	Panel Discussion	





	THE AGA KHAN UN		THE AGA KHAN UNIVERSITY	
12:30 PM – 01:15 PM	Lunch	ınch		
Session 7- Engaging Patients and Communities				
Session Chair 1: Dr. Saral	Session Chair 1: Dr. Sarah Saleem, Section Head Community Health Sciences, AKU			
Session Chair 2: Dr. Imran Nisar, Vice Chair Department of Pediatrics and Child Health, AKU			lealth, AKU	
Time	Title	Speaker		
01:15 PM – 01:30 PM	Bridging Communities and Research	_		
	Facilitating Community-Based Clinica		of Department of	
	Trials		d Child Health, AKU	
01:30 PM – 01:45 PM	Public and Patient Engagement	Dr. Timo Tol	•	
04.45 DM 00.00 DM	Malay Avidian aliminal Aviala in law	Global Health		
01:45 PM – 02:00 PM	Malnutrition clinical trials in low-	Dr. Isabel Po Scientific Adv		
	and middle-income countries		Clinical Trials in Low	
		Income Comr		
		Pharma Solut	*	
02:00 PM – 02:15 PM	Upscaling Human Capacity in	Shelly (Shila	an) Sedighi	
	Clinical Trials	President- ACRP Canada Chapter		
		Founder- Qcare Health Research		
		Corporation		
02:15 PM – 02:30 PM	Q & A session			
Session 8- Shaping the Future of Clinical Trials: Innovations and				
Advancements				
Session Chair 1: Dr. Farah Naz Qamar, Associate Dean Research, AKU				
	Session Chair 2: Dr. Abdul Rashid Abdul Rahman, Chairman Scientific Review Panel for Clinical Trials, Malaysia			
02:30 PM – 02:45 PM	WHO- CTU Maturity Framework	Dr. Vasee Moorthy		
		Senior Advisor, F	-	
<u>. </u>		Division, WHO HQ		
02:45 PM – 03:00 PM	Applications of Artificial	Dr. Iftekhar Kh	ian	
	Intelligence (AI) and Machine	•	tatistical Assessor	
	Learning (ML) in Clinical Trials of			
	Drugs and Devices: Regulatory	MHRA		
	and Practical Considerations			
03:00 PM – 03:15 PM	Decentralized Clinical Trials in	Dr. Shaalan Beg		
	Resource-Limited Settings	Adjunct Associa		
		University of Texas, Southwestern Medical School, Dallas, USA		
03:15 PM – 03:35 PM	Plenary Talk:	Prof Andrew P		
23.13.1.1	Use Of Controlled Human	Director of the Oxford Vaccine		
	Infection Models (CHIMs) In	Group and Asha		
	Vaccine Development: The Role	Infection and Im		
	•	University of Oxf		





	of CHIM In Typhoid Vaccine Policy	
03:35 PM – 03:50 PM	Q & A session	

Session 9- Addressing Rare Diseases in Pakistan: Insights and Initiatives Session Chair 1: Dr. Kulsoom Ghias, Chair Biological & Biomedical Sciences, AKU Session Chair 2: Dr. Azhar Hussain, Director Biological and Biomedical Sciences		
03:50 PM – 04:05 PM	Spectrum of Rare Diseases in	Dr. Salman Kirmani
	Pakistan	Chair & Director, Division of Women
		& Child Health, AKU
04:05 PM – 04:20 PM	Launch of the Pakistan Rare	Dr. Javed Akram
	Diseases Society	President, Pakistan Society of
	_	Internal Medicine
04:20 PM – 04:30 PM	Q & A session	
04:30 PM – 04:45 PM	Summary of the Summit and	
	Closing remarks	
	Coffee & Tea	

D